The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines

Author： Muñoz Miguel  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 529-540

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines

By  

Letters in Drug Design & Discovery, Vol. 3, Iss. 5, 2006-07 ,pp. : 323-329

Bentham Science Publishers

Access to resources Recommend Favorite

Aprepitant – a novel NK1-receptor antagonist

By Patel Lisa   Lindley Celeste  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 12, 2003-12 ,pp. : 2279-2296

Informa Healthcare

Access to resources Recommend Favorite

Antiemetic Studies on the NK1 Receptor Antagonist Aprepitant

By Stoutenburg John P.   Raftopoulos Harry  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 5, 2004-09 ,pp. : 491-497

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011

By Muñoz Miguel   Martinez-Armesto Juan   Coveñas Rafael  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 7, 2012-07 ,pp. : 735-746

Informa Healthcare

Access to resources Recommend Favorite

NK 1 (substance P) receptor antagonists - why are they not analgesic in humans?

By Hill R.  

Trends in Pharmacological Sciences, Vol. 21, Iss. 7, 2000-07 ,pp. : 244-246

Elsevier

Access to resources Recommend Favorite